Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible

Pull up Sanofi’s most recent annual report and find the line where dupilumab — marketed as Dupixent — accounts for the single largest driver of company revenue. Then consider that dupilumab’s core composition-of-matter patents will face their first serious biosimilar pressure before the end of this decade. Now look at the April 7, 2026 press release announcing that lunsekimig, Sanofi’s bispecific nanobody targeting both IL-4Rα and IL-33, met its primary and key secondary endpoints in two separate phase 2 studies — one in moderate-to-severe asthma, one in chronic rhinosinusitis with nasal polyps. That is not a coincidence of timing. That is a lifecycle management strategy becoming visible.

The consensus read will celebrate lunsekimig as evidence that Sanofi’s immunology pipeline is deep. Fair enough. But the more commercially important signal is structural: Sanofi is building the next biologic around the same disease territory that made dupilumab a $14 billion annual franchise, while adding a mechanistic upgrade — IL-33 blockade — that dupilumab cannot replicate with a label change or a formulation tweak.

The Mechanism Is the Moat

Dupilumab works by blocking IL-4Rα signaling, which interrupts both IL-4 and IL-13 pathways — the canonical Th2 drivers of atopic inflammation. The clinical community has accepted this as the standard-of-care backbone in type 2 inflammatory disease. But IL-33 operates upstream, acting as an epithelial alarmin that initiates the Th2 cascade before IL-4 and IL-13 ever enter the picture. A molecule that blocks both the initiating signal and the downstream receptor is, at least in theory, attacking the same pathophysiology from two angles simultaneously.

That theory now has phase 2 data behind it in two indications simultaneously.

This is where the competitive intelligence gets interesting. AstraZeneca’s tezepelumab, approved for asthma under the brand name Tezspire, also targets an alarmin — TSLP rather than IL-33 — and AstraZeneca built its entire differentiation argument around the ability to reduce exacerbations in patients with low eosinophil counts, a population dupilumab historically handled less convincingly. That was a smart wedge strategy. But lunsekimig, if its phase 2 profile holds into phase 3, doesn’t cede the eosinophilic patient population to dupilumab while chasing the low-eosinophil patients — it competes across the biomarker spectrum. GSK’s mepolizumab and benralizumab, both IL-5 pathway assets, have been repositioning toward broader type 2 disease for years precisely because the single-pathway story is becoming commercially insufficient. Sanofi, if lunsekimig delivers, would be the first sponsor with a bispecific nanobody that covers the alarmin and the effector receptor in a single molecule across both asthma and upper airway disease.

The CRSwNP data matters as much as the asthma data, and possibly more for near-term commercial positioning. Dupixent’s CRSwNP approval was transformative — it gave ENT physicians a biologic option in a space that had been managed with repeated surgeries and steroids. But the CRSwNP market is still underpenetrated relative to the diagnosed population, and a successor molecule with a differentiated mechanism arriving before dupilumab’s biosimilar window could effectively reset the competitive clock in that indication entirely.

What the BD Desks Are Calculating Tonight

Here is the counterintuitive read that most coverage will miss: the real competitive pressure from lunsekimig’s phase 2 success lands not on dupilumab, but on every mid-sized respiratory immunology asset currently in the partnering market. When a platform technology demonstrates proof-of-concept across two indications in the same phase 2 readout cycle, the risk-adjusted NPV of every competing single-indication biologic in the same space just declined — not because of head-to-head data, but because of narrative gravity. Payers, KOLs, and prescribers will begin constructing the mental model of “what comes after dupilumab,” and lunsekimig is now the leading candidate for that frame.

BD teams at companies holding phase 2 respiratory assets should be stress-testing their partnering timelines against this signal. A bispecific with dual-indication phase 2 success from a sponsor with Sanofi’s commercial infrastructure — the same organization that built dupilumab from a niche atopic dermatitis approval into a multi-indication blockbuster generating Regeneron royalties that have reshaped that company’s entire capital allocation — is not a future threat. It is a present-tense competitive constraint on valuation multiples in the type 2 inflammation space.

Regeneron, Sanofi’s longtime collaborator on dupilumab, is the entity that deserves the most scrutiny in this context. The dupilumab profit-sharing arrangement has been central to Regeneron’s financial model — Regeneron’s share of Dupixent collaboration profits reached multi-billion dollar levels annually by the mid-2020s, according to the company’s SEC filings and earnings transcripts. Lunsekimig is a Sanofi-generated asset, developed through the Ablynx nanobody platform that Sanofi acquired. It does not, as currently structured, carry the same Regeneron collaboration economics. If lunsekimig eventually displaces dupilumab volume in respiratory indications — even partially — the downstream economics of that transition favor Sanofi’s margin profile in ways that the top-line revenue comparison alone will not capture.

The Phase 3 Decisions No One Has Made Yet

Phase 2 success in two indications simultaneously is a capital allocation moment, not a victory lap. Sanofi now faces the design question that will determine whether lunsekimig becomes a $3 billion asset or a $300 million niche product: does phase 3 go head-to-head against dupilumab, or does it pursue superiority over standard of care with dupilumab as background therapy in a subpopulation? The answer to that question will be visible in the ClinicalTrials.gov registration and the FDA Type B meeting request, not in the press release.

The precedent worth examining is AstraZeneca’s development of tezepelumab, which was designed specifically to avoid a head-to-head comparison with dupilumab by carving out the low-eosinophil and oral corticosteroid-dependent patient segments — a regulatory and commercial decision that gave tezepelumab a defensible market position without generating the kind of comparative effectiveness data that would have made payer negotiations more difficult. Sanofi has the option to run a similar playbook. But given that lunsekimig’s dual mechanism theoretically supports a broader efficacy claim, the temptation to design for superiority will be real. And a phase 3 program designed to beat dupilumab head-to-head — even one run by the same company — is a nine-figure clinical investment on a trial outcome that regulators and payers will read with maximum scrutiny.

The Ablynx nanobody platform, which Sanofi acquired for roughly €3.9 billion in 2018, has been waiting for a phase 2 readout like this one to justify the strategic logic of that acquisition at a premium. Caplacizumab, among the first approved nanobodies, validated the format in a rare hematologic disease. Lunsekimig would be the first nanobody-based asset to compete directly in a mass-market chronic disease category against entrenched monoclonal antibody franchises. If the phase 3 program is designed correctly, Sanofi is not just defending dupilumab’s revenue — it is demonstrating that the nanobody format can carry blockbuster-scale commercial weight. Every other company that has licensed or developed nanobody-format assets is watching this program as a valuation benchmark.

Sanofi’s pipeline presentation at the next major investor conference will draw a straight line from lunsekimig’s phase 2 success to a multi-indication development plan spanning asthma, CRSwNP, and possibly atopic dermatitis — the indication where dupilumab first launched and where the biosimilar threat is most immediate. When that slide deck drops, the question to ask isn’t whether lunsekimig works. Two phase 2 primary endpoints say it works. The question is whether Sanofi has the regulatory nerve to design a phase 3 that proves it works better — and whether the commercial team can execute a successor launch against a product they spent a decade building into the market’s default answer for type 2 inflammation.

References

1. GlobeNewswire — “Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP” (April 2026)
2. Sanofi Annual Report — Dupixent revenue and pipeline disclosures (2025)
3. Regeneron Pharmaceuticals SEC Filing (10-K) — Dupixent collaboration profit-sharing arrangement and annual collaboration revenue figures
4. Sanofi Press Release — Acquisition of Ablynx NV, transaction value and nanobody platform rationale (2018)
5. FDA Guidance — Development of Drugs for Type 2 Inflammatory Diseases and Asthma Biomarker Stratification